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HTLV-1 expression is maintained at low levels in vivo
through unknown mechanisms. Interferon-a (IFN-a)
has been used in combination with zidovudin (AZT) to
treat adult T-cell leukemia/lymphoma (ATL) patients
with favorable effects, although the mechanism is also
unclear. We previously reported that HTLV-1 gene
expression could be markedly suppressed by stromal
cells through a type-I IFN response in IL-2-dependent
HTLV-1-infected T-cells (ILTs) derived from ATL
patients. Here, we found that treatment with IFN-a alone
produced suppressive effects on HTLV-1 gene expression
in ILTs and also on the spontaneous HTLV-1 induction
in short-term cultured primary ATL cells. Following
IFN-a treatment, the levels of intracellular Tax protein
decreased earlier than those of HTLV-1 mRNA in ILTs.
An RNA-dependent protein kinase (PKR) inhibitor
reversed IFN-a-mediated suppression of Tax in ILTs,
suggesting the involvement of a post-transcriptional
mechanism mediated by PKR in the suppression. IFN-a
also induced cell cycle arrest at the G0/G1 phase in ILTs.
We further found that AZT combined with IFN-a
induced cell apoptosis in ILTs, associated with phosphor-
ylation of p53 and enhanced expression of genes respon-
sive to p53, whereas AZT alone did not affect cell
viability or viral expression. Our results suggest that ILTs
and ATL cells retain susceptibility to type-I IFNs, which
suppress HTLV-1 gene expression primarily at a post-
transcriptional level and potentially allow for signaling
through the p53 pathway in combination with AZT.
These findings would partly explain how HTLV-1 gene
expression is regulated in vivo, and how AZT/IFN-a pro-
duces therapeutic effects in ATL.
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